Human Pneumococcal IgG Multiplex by Quansys Biosciences

Biotechno Labs as the channel partner of Quansys Biosciences is proud to introduce the scientific community with Quansys Biosciences’ recently launched  Human Pneumococcal IgG Multiplex. Quansys Biosciences Inc builds and develops customizable multiplex and singleplex assay technologies that allow pharmaceutical companies, clinical laboratories, government institutions, universities, and academics around the world access to large amounts of quantitative data quickly and efficiently. The Q-Plex Array Technology makes it possible to measure up to 18 analytes at one time without compromising assay performance. Quick read times, customization, and highly sensitive assays help researchers to better understand the disease and improve their biological sample testing.

The bacterium Streptococcus pneumoniae can cause potentially deadly infections in children and the elderly, including pneumonia and meningitis. Antibodies play an essential role in the protection against pneumococcal disease. In humans, serum antibodies typically act against the polysaccharide capsule in a serotype-specific manner. There are multiple vaccination options for protection against S. pneumoniae, with the major difference being the number and composition of specific serotypes present in the vaccine. The Q-Plex™ Human Pneumococcal IgG (23-Plex) is a chemiluminescent multiplex ELISA run on two 96-well plates comprising the serotypes found in the Pneumovax®23 vaccine.